Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes.

[1]  J. Rosenstock,et al.  Glimepiride, a New Once-Daily Sulfonylurea: A double-blind placebo-controlled study of NIDDM patients , 1996, Diabetes Care.

[2]  U. Kintscher,et al.  Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity , 2004, Circulation.

[3]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[4]  M. Matsuda,et al.  Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. , 2003, Diabetes.

[5]  A. Greenberg,et al.  The Short- and Long-Term Effects of Tumor Necrosis Factor-α and BRL 49653 on Peroxisome Proliferator-Activated Receptor (PPAR)γ2 Gene Expression and Other Adipocyte Genes , 1998 .

[6]  E. Draeger,et al.  Clinical profile of the novel sulphonylurea glimepiride. , 1996, Diabetes research and clinical practice.

[7]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[8]  Clark He,et al.  The Effect of Glimepiride on Pancreatic β-Cell Function Under Hyperglycaemic Clamp and Hyperinsulinaemic, Euglycaemic Clamp Conditions in Non-Insulin-Dependent Diabetes Mellitus , 1996 .

[9]  H. Katagiri,et al.  Regulation of PPARγ transcriptional activity in 3T3-L1 adipocytes , 2003 .

[10]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[11]  W. Wahli,et al.  Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. , 2000, Molecular endocrinology.

[12]  D. Hardie,et al.  5′-AMP-activated Protein Kinase Phosphorylates IRS-1 on Ser-789 in Mouse C2C12 Myotubes in Response to 5-Aminoimidazole-4-carboxamide Riboside* , 2001, The Journal of Biological Chemistry.

[13]  G. Müller.  The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl , 2000, Molecular medicine.

[14]  G. Müller,et al.  The Sulfonylurea Drug, Glimepiride, Stimulates Glucose Transport, Glucose Transporter Translocation, and Dephosphorylation in Insulin-Resistant Rat Adipocytes In Vitro , 1993, Diabetes.

[15]  J. Clement,et al.  Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. , 1995, Science.

[16]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. , 2004, Hypertension.

[17]  B. Spiegelman,et al.  A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Toshio Hayashi,et al.  Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. , 2003, Diabetes care.

[19]  B. Spiegelman,et al.  Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. , 1996, Molecular endocrinology.

[20]  M. Stumvoll,et al.  Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide. , 2002, Diabetes care.

[21]  Bruce M. Spiegelman,et al.  Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ , 1996, Science.

[22]  W. Wilkison,et al.  Upregulation of adipocyte metabolism by agouti protein: possible paracrine actions in yellow mouse obesity. , 1996, The American journal of physiology.

[23]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[24]  C. Rosak.  The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. , 2002, Journal of diabetes and its complications.

[25]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[26]  S. O’Rahilly,et al.  Induction of Adipocyte Complement-related Protein of 30 Kilodaltons by Ppar␥ Agonists: a Potential Mechanism of Insulin Sensitization , 2022 .

[27]  K. Inukai,et al.  Efficacy of glimepiride in Japanese type 2 diabetic subjects. , 2005, Diabetes research and clinical practice.

[28]  C. Kahn,et al.  Cross-talk between the insulin and angiotensin signaling systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Y. Yazaki,et al.  Overexpression of Catalytic Subunit p110α of Phosphatidylinositol 3-Kinase Increases Glucose Transport Activity with Translocation of Glucose Transporters in 3T3-L1 Adipocytes* , 1996, The Journal of Biological Chemistry.

[30]  J. Balfour,et al.  Glimepiride , 1998, Drugs.